doi:10.16150/j.1671-2870.2021.05.001

Abstract

CLC Number:

R715.2

References 39

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021,71(3):209-249. doi: 10.3322/caac.21660 URL
[2]	Man XB, Tang L, Zhang BH, et al. Upregulation of Glypi-can-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers[J]. Liver Int, 2005,25(5):962-966. doi: 10.1111/j.1478-3231.2005.01100.x URL
[3]	Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study[J]. Lancet Oncol, 2012,13(8):817-826. doi: 10.1016/S1470-2045(12)70233-4 URL
[4]	Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011,29(36):4781-4788. doi: 10.1200/JCO.2011.38.2697 URL
[5]	Wang HL, Anatelli F, Zhai QJ, et al. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions[J]. Arch Pathol Lab Med, 2008,132(11):1723-1728. doi: 10.5858/132.11.1723 URL
[6]	Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders[J]. Gut, 2001, 48(4):558-564. pmid: 11247902
[7]	Fu J, Wang H. Precision diagnosis and treatment of liver cancer in China[J]. Cancer Lett, 2018,412:283-288. doi: 10.1016/j.canlet.2017.10.008 URL
[8]	Qin QF, Weng J, Xu GX, et al. Combination of serum tumor markers dickkopf-1, DCP and AFP for the diagnosis of primary hepatocellular carcinoma[J]. Asian Pac J Trop Med, 2017,10(4):409-413. doi: S1995-7645(16)30238-3 pmid: 28552111
[9]	Ringelhan M, Pfister D, O′Connor T, et al. The immuno-logy of hepatocellular carcinoma[J]. Nat Immunol, 2018, 19(3):222-232. doi: 10.1038/s41590-018-0044-z pmid: 29379119
[10]	Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrati-ng T cells in liver cancer revealed by single-cell sequencing[J]. Cell, 2017,169(7):1342-1356. doi: 10.1016/j.cell.2017.05.035 URL
[11]	Chikuma S, Kanamori M, Mise-Omata S, et al. Suppressors of cytokine signaling: potential immune checkpoint molecules for cancer immunotherapy[J]. Cancer Sci, 2017, 108(4):574-580. doi: 10.1111/cas.13194 URL
[12]	Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of re-gulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection[J]. J Clin Oncol, 2007,25(18):2586-2593. doi: 10.1200/JCO.2006.09.4565 URL
[13]	Devalaraja S, To TKJ, Folkert IW, et al. Tumor-derived retinoic acid regulates intratumoral monocyte differentiation to promote immune suppression[J]. Cell, 2020,180(6):1098-1114,e16. doi: S0092-8674(20)30219-1 pmid: 32169218
[14]	Pauken KE, Torchia JA, Chaudhri A, et al. Emerging concepts in PD-1 checkpoint biology[J]. Semin Immunol, 2021,52:101480. doi: 10.1016/j.smim.2021.101480 URL
[15]	Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade[J]. Science, 1996, 271(5256):1734-1736. doi: 10.1126/science.271.5256.1734 pmid: 8596936
[16]	Fan F, Chen K, Lu X, et al. Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma[J]. Hepatol Int, 2021,15(2):444-458. doi: 10.1007/s12072-020-10101-6 URL
[17]	Ma LJ, Feng FL, Dong LQ, et al. Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma[J]. Theranostics, 2018,8(20):5690-5702. doi: 10.7150/thno.28742 URL
[18]	Lee DH, Lee MW, Kim PN, et al. Outcome of no-touch radiofrequency ablation for small hepatocellular carcinoma: a multicenter clinical trial[J]. Radiology, 2021,301(1):229-236. doi: 10.1148/radiol.2021210309 URL
[19]	Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390. doi: 10.1056/NEJMoa0708857 URL
[20]	Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009,10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7 URL
[21]	Marrero JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study[J]. J Hepatol, 2016, 65(6):1140-1147. doi: S0168-8278(16)30346-4 pmid: 27469901
[22]	Qin S, Bi F, Gu S, et al. Donafenib versus Sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase Ⅱ-Ⅲ trial[J]. J Clin Oncol, 2021,39(27):3002-3011. doi: 10.1200/JCO.21.00163 URL
[23]	Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9 URL
[24]	Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021,6(7):559-568. doi: 10.1016/S2468-1253(21)00109-6 URL
[25]	Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012,366(26):2443-2454. doi: 10.1056/NEJMoa1200690 URL
[26]	El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017,389(10088):2492-2502. doi: S0140-6736(17)31046-2 pmid: 28434648
[27]	Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 tria[J]. Lancet Oncol, 2018, 19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6 URL
[28]	Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase Ⅲ Trial[J]. J Clin Oncol, 2020,38(3):193-202.
[29]	Liu Y, Chen X, Han W, et al. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia[J]. Drugs Today (Barc), 2017,53(11):597-608. doi: 10.1358/dot.2017.53.11.2725754 URL
[30]	Liu Y, Chen X, Han W, et al. A guide to manufacturing CAR T cell therapies[J]. Drugs Today (Barc), 2017,53(11):597-608. doi: 10.1358/dot.2017.53.11.2725754 URL
[31]	Gao H, Li K, Tu H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma[J]. Clin Cancer Res, 2014,20(24):6418-6428. doi: 10.1158/1078-0432.CCR-14-1170 URL
[32]	Dargel C, Bassani-Sternberg M, Hasreiter J, et al. T cells engineered to express a T-cell receptor specific for Glypi-can-3 to recognize and kill hepatoma cells in vitro and in mice[J]. Gastroenterology, 2015,149(4):1042-1052. doi: 10.1053/j.gastro.2015.05.055 URL
[33]	Li W, Guo L, Rathi P, et al. Redirecting T cells to Glypi-can-3 with 4-1BB Zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity[J]. Hum Gene Ther. 2017 May; 28(5):437-448. doi: 10.1089/hum.2016.025 URL
[34]	Liu H, Xu Y, Xiang J, et al. Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer[J]. Clin Cancer Res, 2017,23(2):478-488. doi: 10.1158/1078-0432.CCR-16-1203 URL
[35]	Heidbuechel JPW, Engeland CE. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emer-ging immunovirotherapies[J]. J Hematol Oncol, 2021,14(1):63. doi: 10.1186/s13045-021-01075-5 URL
[36]	Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer[J]. Nat Med, 2013,19(3):329-336. doi: 10.1038/nm.3089 URL
[37]	Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study[J]. Lancet Oncol, 2020,21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X URL
[38]	Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020,382(20):1894-1905. doi: 10.1056/NEJMoa1915745 URL
[39]	Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1 immunotherapy[J]. Cell, 2018,174(4):1031-1032. doi: 10.1016/j.cell.2018.07.035 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 39

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 425-430.
[2]	. [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 419-424.
[3]	HUANG Chen, JING Feng, YANG Zhitao, et al . Exploration and practice of construction of nursing management system in shelter hospital [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 286-290.
[4]	LIANG Jing, HUANG Chen, JIANG Yan, et al . Management strategy of nursing for prevention and control of COVID-19 in emergency infusion room [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 281-285.
[5]	ZHANG Hong, ZHU Mengmeng, et al . Safety nursing for eating in the elderly during the COVID-19 pandemic [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 277-280.
[6]	ZHOU Jianping, YANG Zhenhua, WANG Yichen, et al . Practice and thinking of the medical team of the elderly medical assistance center in the prevention and control of COVID-19 in Shanghai [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 265-269.
[7]	ZHA Qinghua, WANG Xiaoning, ZHANG Yin, et al . Exploration and practice of nucleic acid sampling outside hospital during the epidemic period of COVID-19 pandemic [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 229-233.
[8]	YU Ping, QIU Weiyu, WANG Xu, et al . Practice and exploration of drug security management in large shelter hospitals [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 221-224.
[9]	JIANG Yan, LIN Wei, HUANG Chen, et al . Exploration and practice of emergency supplies management mode in emergency department under COVID-19 pandemic [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 212-215.
[10]	TANG Jie, MA Longxin, CAO Qing, et al . Study on the construction of smart shelter hospital based on new generation information technology [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 196-204.
[11]	JIANG Yan, CHEN Ting, HUANG Chen, PAN Peiqian, JING Feng, et al . Construction and practice of emergency response capability training program for all staff in emergency medical ward under COVID-19：Emergency response strategy [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 189-195.
[12]	MENG Jun, JIN Peipei, CHEN Changqiang, CHEN Jiuming, FAN Zhenjia, CHEN Shikai, DAI Jing, et al . Emergency transformation experience of the laboratory department of a hospital designated for admission of patients with novel coronavirus infection in emergency conversion [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 184-188.
[13]	SHI Yingying, ZHONG Xu, LIU Jialin, HE Le, XIONG Shaoji, WENG Y, DING Chengwei, YANG Y, CHEN Weihon, QIU Liping, XIN Haiguang. Hospital infection prevention and control practices in anti-epidemic medical staff and workers during COVID-19 epidemic: investigation and countermeasures [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 178-183.
[14]	DING Ning, CHEN Shikai, MENG Jun, DAI Jing, JIN Peipei, et al . Correlation and influencing factors analysis of the cycle threshold value in detection of novel coronavirus nucleic acid(Omicron) and the negative conversion cycle in infected patients [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 169-173.
[15]	YANG Zhitao, CHEN Ying, JING Feng, XIE Zhihui, ZHANG Yibo, SHANG Hanbin, LIN Jingsheng, WU Wenjuan, GU Zhidong, BI Yufang, CHEN Erzhen. Practice and Exploration on the construction of medical affairs management system in large Fangcang hospitals [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 154-159.